Hepatitis B: Transmission, Symptoms, and Treatment

Roughly 240 million people worldwide were living with chronic hepatitis B in 2024, and the virus causes an estimated 1.1 million deaths each year – primarily from cirrhosis and liver cancer, according to the World Health Organization. There are still about 0.9 million new infections annually worldwide, and most people who are infected do not know it: the WHO estimates only about 27% of those living with chronic hepatitis B have been diagnosed, and only a small fraction are on treatment. In the United States, the CDC estimates that roughly 640,000 adults have chronic hepatitis B – and because the disease is often silent and underdiagnosed, especially among people born in higher-prevalence regions, some studies put the true number higher. A safe, effective vaccine has been available since 1982, yet new infections continue, and the burden of chronic disease acquired before widespread vaccination remains enormous. This guide covers transmission, symptoms, screening, treatment, and the ongoing search for a cure. For related conditions, see our medical conditions guide.

What Is Hepatitis B?

Hepatitis B is a viral infection caused by the hepatitis B virus (HBV), which targets liver cells (hepatocytes). The virus replicates within the liver, and the immune system’s attempt to clear the infection causes inflammation and liver damage. Paradoxically, it is the body’s immune response – not the virus itself – that causes most of the liver injury. HBV is a DNA virus belonging to the Hepadnaviridae family, and its unique replication strategy, which involves an RNA intermediate and integration into the host’s DNA, makes it particularly difficult to eradicate completely.

The infection can be acute (a short-term illness in which the immune system clears the virus within six months) or chronic (the virus persists for more than six months and, without treatment, often for life). The risk of developing chronic infection depends heavily on the age at which infection occurs. According to the CDC, approximately 90% of infected infants develop chronic infection, compared with 25-50% of children infected between ages 1 and 5, and less than 5% of otherwise healthy adults infected after age 5. This is the single most important fact about hepatitis B epidemiology: the earlier in life infection happens, the more likely it is to become lifelong.

This age-dependent relationship is crucial for understanding the global pattern of hepatitis B. In regions where the virus is highly endemic – parts of East Asia, sub-Saharan Africa, and the Pacific Islands – most transmission occurs perinatally (from mother to child at birth) or in early childhood, leading to high rates of chronic infection. In lower-prevalence regions like the United States and Western Europe, most infections occur in adulthood through sexual contact or injection drug use, and the majority of these resolve on their own. This is also why a large share of US chronic infections are found in people born in higher-prevalence countries, which is one reason universal screening has become the recommended approach.

How Hepatitis B Is Transmitted

HBV is transmitted through contact with infected blood or body fluids, including semen and vaginal fluids. The virus is highly infectious – far more so than HIV – and it can survive outside the body on surfaces for at least seven days and still cause infection during that time. Major routes of transmission include:

• Perinatal: from an infected pregnant person to the baby during birth – the most important route worldwide because infant infection so often becomes chronic.
• Sexual contact with an infected partner.
• Sharing needles, syringes, or drug-preparation equipment.
• Needlestick injuries and other blood exposures in healthcare settings.
• Sharing personal items that may carry traces of blood, such as razors, toothbrushes, or glucose-monitoring equipment.

Hepatitis B is not spread through casual contact – hugging, sharing utensils, coughing, sneezing, or ordinary food and water. Breastfeeding by a mother with hepatitis B is generally considered safe when the infant has received the recommended birth-dose vaccine and immune globulin. In some endemic regions, traditional practices such as tattooing, scarification, or procedures using unsterilized instruments contribute to transmission.

Screening of the blood supply has virtually eliminated transfusion-related transmission in countries with modern blood-banking systems. Universal infant vaccination, recommended by the WHO and implemented in the US since the early 1990s, has dramatically reduced new infections in younger cohorts. Despite these advances, new HBV infections still occur every year in the US, mostly among unvaccinated adults – which is exactly why adult vaccination recommendations were broadened.

Symptoms of Acute and Chronic Infection

Acute hepatitis B has an incubation period of roughly six weeks to six months. Many people – particularly young children – have no symptoms at all. When symptoms occur, they may include fatigue, loss of appetite, nausea and vomiting, abdominal pain (especially in the upper right quadrant), dark urine, clay-colored stools, joint pain, and jaundice (yellowing of the skin and eyes). Most otherwise healthy adults with acute hepatitis B recover fully within a few months and develop lifelong immunity.

Fulminant (acute liver failure) hepatitis is a rare but life-threatening complication of acute infection. It involves massive liver injury, bleeding problems, and hepatic encephalopathy (confusion caused by toxins the liver can no longer clear), and it may require emergency hospitalization and even liver transplantation. The risk is higher in people also infected with hepatitis D virus (HDV), which can only replicate in the presence of HBV.

Chronic hepatitis B is usually silent for years or decades. When symptoms finally develop, they often reflect advanced liver disease: persistent fatigue, abdominal pain, spider angiomas (small, spider-shaped blood vessels visible on the skin), easy bruising or bleeding, ascites (fluid in the abdomen), leg swelling, and hepatic encephalopathy. By that point, significant liver scarring – cirrhosis – has often already developed. Because the damage is silent, testing rather than symptoms is what catches most chronic infections in time.

Screening and Diagnosis

The CDC recommends that all adults aged 18 and older be screened for hepatitis B at least once in their lifetime, and that all pregnant people be screened during each pregnancy. This universal, one-time screening replaced older risk-based guidelines, which missed many infected people because risk factors are not always disclosed or recognized. People with ongoing risk – and those born in regions where hepatitis B is common – may be tested more often, based on clinical judgment.

The initial screening test is the hepatitis B surface antigen (HBsAg), which indicates active infection. A complete assessment usually adds several markers:

• Anti-HBs (hepatitis B surface antibody): indicates immunity – either from a resolved past infection or from vaccination.
• Anti-HBc (hepatitis B core antibody): indicates past or present infection. IgM anti-HBc suggests recent, acute infection; total anti-HBc persists for life after any exposure.
• HBeAg (hepatitis B e antigen): a marker often associated with high viral replication and infectivity.
• HBV DNA (viral load): quantifies the amount of virus in the blood and helps guide treatment decisions.

For people with chronic hepatitis B, further evaluation includes liver function tests (ALT, AST), a complete blood count, assessment for liver fibrosis (using non-invasive methods such as elastography or blood-based fibrosis markers), testing for hepatitis D co-infection, and periodic imaging (ultrasound) for liver-cancer surveillance. Liver biopsy, once routine, has largely been replaced by non-invasive fibrosis assessment except in ambiguous cases. Interpreting this panel is a job for a clinician – the same marker can mean very different things depending on the full picture.

Treatment of Chronic Hepatitis B

Not everyone with chronic hepatitis B needs antiviral treatment. Treatment decisions depend on the phase of infection (judged from HBeAg status, HBV DNA level, ALT levels, and fibrosis stage), the presence of cirrhosis, and special circumstances such as pregnancy, immunosuppression, or planned chemotherapy. The American Association for the Study of Liver Diseases (AASLD) publishes detailed guidance on when to start treatment – and that decision should always be made with a hepatologist or gastroenterologist, not self-directed.

Two broad classes of medication are approved. Nucleos(t)ide analogs – a group that includes entecavir and tenofovir formulations – are the most commonly used. They suppress viral replication, are taken as a daily oral pill, have an excellent safety profile, and achieve viral suppression in the large majority of patients. However, they rarely achieve a “functional cure” (loss of HBsAg), and most people need indefinite treatment because stopping often leads to viral rebound. The other option, pegylated interferon, works by boosting the immune response and has the advantage of a finite treatment course, but it causes significant side effects (flu-like symptoms, mood changes, low blood counts) and helps only a select group of patients.

This guide deliberately does not list doses. The right medicine, dose, and duration are individualized and must be chosen and monitored by the treating clinician – some antivirals require kidney or bone monitoring, some interact with other conditions, and stopping abruptly can be harmful. According to research summarized by the AASLD, combination strategies and novel agents aimed at HBsAg reduction are under active investigation. If you have chronic hepatitis B, the most important step is establishing care with a specialist who can decide whether and how to treat.

Medication, Alcohol, and Everyday Liver Safety

Because hepatitis B already stresses the liver, everyday choices matter. Alcohol accelerates liver damage and raises the risk of cirrhosis and liver cancer; most hepatologists advise avoiding it entirely, and complete abstinence is strongly recommended for anyone with fibrosis or cirrhosis. Acetaminophen (Tyladenol/paracetamol) can be used cautiously by many people with liver disease, but it is dose-sensitive and is found in many combination cold, flu, and pain products, so it is easy to exceed safe limits by accident – ask your clinician or pharmacist what daily limit is safe for you, and never combine it with alcohol. Other over-the-counter medicines, supplements, and herbal products (including some marketed for “liver health”) can also stress the liver, so review everything you take with your care team. Do not start, stop, or change any medicine based on this article.

Liver Cancer Surveillance

Chronic hepatitis B significantly increases the risk of hepatocellular carcinoma (HCC), the most common primary liver cancer. HBV is unusual among hepatitis viruses in that it can cause HCC even without cirrhosis, because of viral DNA integration into the host genome and the direct effects of certain viral proteins. The risk is highest with cirrhosis, persistently high viral loads, older age, male sex, family history of liver cancer, and co-infection with hepatitis C or D.

Guidelines from the AASLD and others recommend regular HCC surveillance – typically abdominal ultrasound, sometimes with a blood marker (alpha-fetoprotein), every six months – for people at higher risk, including all patients with cirrhosis and certain non-cirrhotic patients based on age, family history, and background. Early detection dramatically improves outcomes: small tumors found through surveillance are often treatable with surgery or ablation, while advanced liver cancer has a much poorer prognosis. Antiviral therapy lowers but does not eliminate HCC risk, which is why surveillance continues even when the virus is suppressed. Planning for the cost of ongoing monitoring and treatment is part of managing the condition well.

Prevention: Vaccination and Beyond

The hepatitis B vaccine is one of the most effective vaccines ever developed, with protection exceeding 90-95% after a complete series. Current CDC and Advisory Committee on Immunization Practices (ACIP) recommendations call for:

• A birth dose for all newborns, followed by completion of the series in infancy.
• Vaccination of all previously unvaccinated children and adolescents.
• Universal vaccination of adults aged 19-59.
• Vaccination of adults 60 and older who have risk factors – and, for those without known risk factors, vaccination is still an option they can choose through shared decision-making with their clinician.

This universal adult recommendation (through age 59) is a meaningful change from the older, risk-based approach, and it means most adults who were never vaccinated as children are now candidates. For newborns of HBsAg-positive mothers, a birth-dose vaccine within 12 hours combined with hepatitis B immune globulin (HBIG) is highly effective at preventing perinatal transmission – a critical step given how often infant infection becomes chronic. Antiviral therapy during the third trimester for mothers with high viral loads can further reduce transmission risk, under specialist guidance.

Post-exposure prophylaxis with HBIG and vaccination is available for unvaccinated people exposed to HBV through needlestick injuries, sexual contact, or other routes. Standard precautions in healthcare settings, safe injection practices, and harm-reduction programs for people who inject drugs are also important. If you are unsure whether you were ever vaccinated, a simple blood test can check your immunity.

The Quest for a Functional Cure

Current antivirals effectively suppress HBV but rarely achieve HBsAg loss – the marker of “functional cure.” The virus’s covalently closed circular DNA (cccDNA), which persists in the nucleus of infected liver cells, acts as a reservoir that today’s drugs do not eliminate. A large global research effort is targeting multiple steps of the HBV lifecycle to change that.

Promising approaches include RNA-interference (siRNA) agents that silence viral RNA production, capsid-assembly modulators that disrupt viral particle formation, drugs aimed at reducing HBsAg, and therapeutic vaccines designed to restore the immune response against HBV. Several candidates are in clinical trials, and the hepatology community is cautiously optimistic that functional cure could become achievable for a meaningful share of patients within the coming years – though it is not available as standard care today, and any claims of a guaranteed “cure” should be treated with skepticism.

Frequently Asked Questions

Can hepatitis B be cured?

Acute hepatitis B resolves on its own in the large majority of otherwise healthy adults. Chronic hepatitis B can be effectively controlled with clinician-directed antiviral medication – suppressing the virus, often to undetectable levels – but a true cure that eliminates the virus from the body is not yet achievable with current therapies. A “functional cure” (durable loss of HBsAg off treatment) occurs in only a small percentage of treated patients today. New therapies in development aim to raise that rate, but they are still experimental.

Is hepatitis B more dangerous than hepatitis C?

Both are serious infections that can cause cirrhosis and liver cancer. Hepatitis C is now curable in the large majority of cases with direct-acting antiviral therapy, while hepatitis B is generally harder to cure. Hepatitis B can also cause liver cancer without cirrhosis, which hepatitis C rarely does – but hepatitis B has an effective preventive vaccine, which hepatitis C does not. The relative danger depends on individual circumstances, access to care, and the stage of disease.

Should I tell people I have hepatitis B?

You should inform sexual partners, household members, and your healthcare providers. Sexual partners should be tested and vaccinated if not already immune, and household members should be vaccinated. There is no general obligation to disclose your status to employers, friends, or the public, and hepatitis B is not transmitted through casual workplace or social contact. Anti-discrimination laws protect people with hepatitis B in employment and other settings.

Can I drink alcohol if I have hepatitis B?

Alcohol accelerates liver damage in people with chronic hepatitis B and increases the risk of cirrhosis and liver cancer. Most hepatologists recommend avoiding alcohol entirely or limiting it to a minimum, and if you have any degree of fibrosis or cirrhosis, complete abstinence is strongly advised. Discuss your specific situation with your clinician.

Do I need the hepatitis B vaccine if I already had the infection?

If you have recovered from hepatitis B (positive anti-HBs and anti-HBc with negative HBsAg), you have natural immunity and do not need the vaccine. If you have chronic hepatitis B (positive HBsAg), the vaccine will not help. The vaccine is for people who have never been infected and lack immunity. A blood test can determine your status.

What to Do Next

If you have never been tested for hepatitis B, get tested – the CDC recommends it at least once for every adult, and it is a simple blood test. If you have not been vaccinated, ask about the vaccine; adults through age 59 are now routinely recommended for it, and many older adults are candidates too. If you have chronic hepatitis B, establish care with a hepatologist or gastroenterologist, attend all liver-cancer surveillance appointments, take antiviral medication only as prescribed and monitored, and avoid alcohol.

Hepatitis B is a manageable condition with proper care and monitoring. The goal is to prevent liver damage, catch complications early, and – as the science advances – move toward a cure. Stay informed, stay connected with your healthcare team, and do not let stigma keep you from the care you deserve. This article is general education only and is not a substitute for advice from a qualified clinician.

Sources

• World Health Organization – Hepatitis B fact sheet (2024 estimates): who.int
• CDC – Hepatitis B (About, Vaccination, Screening & Testing): cdc.gov/hepatitis-b
• MedlinePlus (U.S. National Library of Medicine) – Hepatitis B: medlineplus.gov
• AASLD – Hepatitis B Guidance: aasld.org